Study Evaluating a New Stool Test Panel M3 and FIT to Detect Recurrence of Advanced Colorectal Adenomas in Adults with Previous Colonic Adenomas

What this Trial Is About

Colorectal cancer is a common cancer with increasing cases among younger people worldwide. Early detection and removal of colonic adenomas can reduce deaths related to colorectal cancer. Researchers are investigating the accuracy of a new panel of four bacterial gene markers, called M3, and the faecal immunochemical test FIT to detect advanced adenomas that return in patients who previously had colonic adenomas. The study compares the diagnostic accuracy of FIT and M3, which includes markers Fn, m3, Ch, and Bc, by analyzing stool samples. Participants have a history of colorectal adenomas identified during their previous colonoscopy. This observational study follows patients over three years to assess how well these tests detect recurrent advanced adenomas. Participants will undergo surveillance colonoscopies and provide stool samples for testing with FIT and the M3 panel. Researchers will measure the sensitivity and specificity of these tests in detecting advanced, non-advanced, and all adenomas at year three. The study monitors participants for three years to evaluate these diagnostic tools performance in identifying adenoma recurrence.

Diagnostic Accuracy of M3 in Predicting Colorectal Advanced Adenoma Recurrence (M3-AA)